ArticleThe Journal of biological chemistry2025
Molecular consequences of SCA5 mutations in the spectrin-repeat domains of β-III-spectrin.
Article in The Journal of biological chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Impaired motor activity in a CRISPR SCA5 L253P knock-in mouse is associated with selective β-III-spectrin subcellular redistribution in the cerebellum.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
- Update of
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinocerebellar ataxia type 5 (SCA5) mutations in the protein β-III-spectrin cluster to the N-terminal actin-binding domain (ABD) and the central spectrin-repeat domains (SRDs). We previously reported that a common molecular consequence of ABD-localized SCA5 mutations is increased actin binding. However, little is known about the molecular consequences of the SRD-localized mutations. It is known that the SRDs of β-spectrin proteins interact with α-spectrin to form an α/β-spectrin dimer. In addition, it is known that SRDs neighboring the β-spectrin ABD enhance actin binding. Here, we tested the impact of the SRD-localized R480W and E532_M544del mutations on the binding of β-III-spectrin to α-II-spectrin and actin. R480W is associated with a severe infantile onset form of SCA5, while E532_M544del is associated with milder symptoms that begin in adulthood. We show that both the R480W and E532_M544del mutants can bind α-II-spectrin. However, E532_M544del causes partial uncoupling of complementary SRDs in the α/β-spectrin dimer. Further, the R480W mutant forms large intracellular inclusions when coexpressed with α-II-spectrin in cells, supporting that R480W grossly disrupts the α-II/β-III-spectrin complex. Moreover, actin-binding assays show that E532_M544del, but not R480W, increases β-III-spectrin actin binding. Additionally, we demonstrate that R480W α-II/β-III-spectrin inclusions contain F-actin, accumulate the spectrin-binding protein ankyrin-R, and localize immediately adjacent to the Golgi complex. Two additional infantile onset mutations, R437W and R437Q, but not the adult onset T472M mutation, also cause formation of large α-II/β-III-spectrin inclusions. We suggest that the intracellular inclusions caused by R480W, R437W, and R437Q drive the more severe disease symptoms associated with these mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.